Singapore: Mundipharma, global pharmaceutical company with operations in Singapore, has entered into a license agreement with German company Grünenthal Group for the exclusive rights to develop, manufacture and commercialize Transtec, an analgesic patch approved in Europe for the treatment of moderate-to-severe cancer pain and severe non-malignant pain that does not respond to non‑opioid analgesics, in Asia Pacific, Middle East and Africa.

The product was the first of its type to contain buprenorphine, a semi-synthetic opioid that depending on dosage strength can be used to control moderate to severe pain. The efficacy of Transtec as a transdermal buprenorphine patch has been demonstrated in multiple clinical trials and studies. It has proven to reduce pain intensity and improve pain relief for cancer pain patients.

The treatment option is suitable for addressing the issue of severe pain in the elderly since it combines analgesic efficacy with a broad safety margin. Moreover, the effect of the buprenorphine patch on quality of life has been investigated in a retrospective study, where it was found that substantial pain relief was accompanied with improvements in physical, psychological and social well-being.

"With Transtec, we hope to provide healthcare professionals access to a viable treatment option for the pressing issues of cancer and severe pain management," said Mr. Raman Singh, President of Mundipharma Asia Pacific, Latin America, Middle East and Africa. "This partnership further reinforces our commitment to continue bringing leading pain management technologies to under-served patients around the world, helping them manage their pain and assist them in the quality of their lives on a daily basis."